Literature DB >> 19362305

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer.

Mohamed F Mitwally1, Michael P Diamond, Mostafa Abuzeid.   

Abstract

OBJECTIVE: To study the outcome of IVF-ET in women who used vaginal P (vaginal P(4)) versus those who used P in oil via IM injection (IM-P(4)) for luteal support.
DESIGN: Retrospective cohort.
SETTING: Tertiary referral infertility center. PATIENT(S): A cohort of 544 women. INTERVENTION(S): In 145 women, vaginal P(4) was used, while in 399 women, IM-P(4) was used for luteal support. MAIN OUTCOME MEASURE(S): The primary outcome was ongoing pregnancy rate. Secondary outcomes included other IVF-ET outcomes: rates of clinical pregnancy and pregnancy loss (chemical and miscarriage) and serum P levels during the luteal phase and early pregnancy. RESULT(S): Women who used vaginal P(4) for luteal support had ongoing pregnancy rates (odds ratio [OR], 1.0675; 95% confidence interval [CI], 0.7587-1.5020) and rates of total pregnancy loss (OR, 1.0775; 95% CI, 0.7383-1.5727) that were not statistically different from those who used IM-P(4). During the luteal phase, women who used vaginal P(4) had mean serum P levels that were not statistically different from those who used IM-P(4). However, during early pregnancy, mean P levels in pregnant women who used vaginal P(4) were statistically significantly higher. CONCLUSION(S): In women undergoing IVF-ET according to the GnRH agonist long protocol, luteal support with vaginal P(4) was associated with treatment outcomes that were no different from those associated with IM-P(4) luteal support. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362305     DOI: 10.1016/j.fertnstert.2009.02.047

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  10 in total

1.  Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial ISRCTN69937179.

Authors:  Mostafa I Abuzeid; Mohamed Mitwally; Yasmine M Abuzeid; Hammad A Bokhari; Mohammad Ashraf; Michael P Diamond
Journal:  J Assist Reprod Genet       Date:  2012-09-08       Impact factor: 3.412

2.  Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support.

Authors:  Angeline N Beltsos; Mark D Sanchez; Kevin J Doody; Mark R Bush; Alice D Domar; Michael G Collins
Journal:  Reprod Health       Date:  2014-11-11       Impact factor: 3.223

3.  Progesterone replacement with vaginal gel versus i.m. injection: cycle and pregnancy outcomes in IVF patients receiving vitrified blastocysts.

Authors:  Daniel B Shapiro; Jennifer A Pappadakis; Nancy M Ellsworth; Howard I Hait; Zsolt Peter Nagy
Journal:  Hum Reprod       Date:  2014-05-20       Impact factor: 6.918

4.  A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest®) for luteal phase support during IVF treatment.

Authors:  Polly Heine; Laura Sellar; Sue Whitten; Priti Bajaj
Journal:  Patient Relat Outcome Meas       Date:  2017-12-08

5.  Intramuscular progesterone versus 8% Crinone vaginal gel for luteal phase support following blastocyst cryopreserved single embryo transfer: a retrospective cohort study.

Authors:  Jennifer B Bakkensen; Catherine Racowsky; Ann M Thomas; Andrea Lanes; Mark D Hornstein
Journal:  Fertil Res Pract       Date:  2020-07-01

6.  Effects of intramuscular and vaginal progesterone supplementation on frozen-thawed embryo transfer.

Authors:  Lei Jiang; Zhuo-Ye Luo; Gui-Min Hao; Bu-Lang Gao
Journal:  Sci Rep       Date:  2019-10-24       Impact factor: 4.379

7.  Progesterone Intramuscularly or Vaginally Administration May Not Change Live Birth Rate or Neonatal Outcomes in Artificial Frozen-Thawed Embryo Transfer Cycles.

Authors:  Yuan Liu; Yu Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-04       Impact factor: 5.555

8.  Effect of Oral versus Vaginal Administration of Estradiol and Dydrogesterone on the Proliferative and Secretory Transformation of Endometrium in Patients with Premature Ovarian Failure and Preparing for Assisted Reproductive Technology.

Authors:  Wenjuan Feng; Longyun Nie; Xiaoyu Wang; Fang Yang; Pan Pan; Xiaohui Deng
Journal:  Drug Des Devel Ther       Date:  2021-04-14       Impact factor: 4.162

9.  A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization.

Authors:  Valerie L Baker; Christopher A Jones; Kevin Doody; Russell Foulk; Bill Yee; G David Adamson; Barbara Cometti; Gary DeVane; Gary Hubert; Silvia Trevisan; Fred Hoehler; Clarence Jones; Michael Soules
Journal:  Hum Reprod       Date:  2014-08-06       Impact factor: 6.918

10.  Effectiveness of high-dose transvaginal progesterone supplementation for women who are undergoing a frozen-thawed embryo transfer.

Authors:  Yihsien Enatsu; Noritoshi Enatsu; Kanako Kishi; Toshiro Iwasaki; Yukiko Matsumoto; Shoji Kokeguchi; Masahide Shiotani
Journal:  Reprod Med Biol       Date:  2018-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.